News and Reports | August 31, 2026
WASHINGTON, D.C. — The White House today announced agreements with nine additional pharmaceutical corporations as part of the administration’s Most Favored Nation (MFN) drug pricing strategy.
Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB have agreed to provide Medicaid programs access to MFN drug prices on their products. However, the terms of the agreements — including how the prices will be implemented and enforced — have not been made public.
In response, P4AD CEO Merith Basey released the following statement:
“For decades, drug companies have been charging Americans at least four times more for brand-name medicines than people in other high-income nations. Patients need systemic reforms that will lower drug prices, rather than short-term, voluntary agreements whose terms remain secret. The deals announced today focus on Medicaid, where steep discounts already exist, and even then, states can choose whether to participate. Lasting relief requires transparent, enforceable measures that lower drug prices and hold big drug companies accountable.”
These new agreements bring the administration’s total number of MFN agreements with pharmaceutical manufacturers to 26. The White House says those manufacturers represent 89 percent of the branded drug market. But that does not mean 89 percent of branded drugs — or 89 percent of patients — will receive MFN prices. The agreements apply only under specific terms and programs, including the Medicaid model.
The administration has not publicly disclosed the full terms of the individual agreements, including the specific prices that will apply to many drugs, how long the commitments will be in effect, how they will be enforced, or what concessions manufacturers may receive in exchange.
###
Patients For Affordable Drugs is the only national patient advocacy organization focused exclusively on policies that lower prescription drug prices. We empower and mobilize patients by amplifying their experiences with high drug prices to hold those in power to account and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4AD does not accept funding from organizations that profit from the development and distribution of drugs. To learn more, visit PatientsForAffordableDrugs.org